Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Equities researchers at Atb Cap Markets cut their FY2025 EPS estimates for shares of Curaleaf in a research note issued to investors on Thursday, August 7th. Atb Cap Markets analyst F. Gomes now forecasts that the company will earn ($0.29) per share for the year, down from their previous forecast of ($0.28). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf's FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.11) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%.
Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a research note on Friday, August 8th.
Check Out Our Latest Report on CURLF
Curaleaf Price Performance
CURLF traded down $0.06 during trading hours on Monday, hitting $3.02. The company's stock had a trading volume of 1,714,788 shares, compared to its average volume of 762,014. Curaleaf has a 12 month low of $0.68 and a 12 month high of $3.58. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -9.44 and a beta of 0.69. The business's 50-day moving average price is $1.19 and its 200-day moving average price is $1.09. The company has a current ratio of 1.47, a quick ratio of 0.70 and a debt-to-equity ratio of 1.00.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access